Tumor Destruction
Tumor Destruction - Related Videos
10:13
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
0 Views •
Cited by 8 •
2022
The present protocol develops an image-based technique for rapid, non-destructive, and label-free regional cell density and viability measurement within 3D tumor aggregates. Findings revealed a cell-density gradient, with higher cell densities in core regions than outer layers in developing aggregates and predominantly peripheral cell death in HER2+ aggregates treated with Trastuzumab.
08:24
Introduction to the Ultrasound Targeted Microbubble Destruction Technique
0 Views •
Cited by 19 •
2011
Ultrasound Targeted Microbubble Destruction (UTMD) can be used to direct site-specific delivery of bioactive molecules, including therapeutic genes, to target organs accessible to ultrasound, such as the heart and liver1-6.
01:12
Non-destructive Tests for Concrete Strength
0 Views •
2024
The rebound hammer test, also known as the Schmidt hammer test, is a non-destructive technique for evaluating the hardness of concrete and, indirectly, the strength of concrete. It operates on the principle that the rebound of a spring-driven mass from a concrete surface correlates to the surface's hardness. The device comprises a mass within a tubular housing, a spring mechanism, and a plunger that strikes the concrete. Upon release, the energy imparted to the mass by the spring causes it to...
07:16
Thermal Ablation for the Treatment of Abdominal Tumors
0 Views •
Cited by 19 •
2011
A thermal tumor ablation procedure is described. The entire procedure is detailed, including pretreatment planning and imaging studies, anesthesia, adjuvant techniques to facilitate a percutaneous approach, imaging guidance of the ablation device to the tumor, thermal treatment, post-treatment care and follow-up.
09:24
Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
0 Views •
Cited by 2 •
2017
A simple and non-destructive technique that measures the average content of drug substances in formulated drug products containing fluorine using low-field fluorine-19 (19F) time-domain (TD) nuclear magnetic resonance (NMR) is presented here. The technique can be applied to the development and manufacturing of drugs in the pharmaceutical industry.
FAQs
Ionizing radiation acts primarily by damaging the DNA of tumor cells. This injury can limit the cells’ ability to survive or reproduce, helping reduce the tumor burden. Its role differs from thermal ablation, which disrupts membranes, proteins, and blood supply through heat or extreme cold. These distinct mechanisms allow treatment planning to reflect tumor characteristics and location.
Thermal ablation uses heat or extreme cold to injure tumor tissue directly. The physical stress can disrupt cell membranes and proteins while also affecting the tumor’s blood supply. Because the effect is localized, the approach may be considered when treatment must focus on a specific tumor region and preserve surrounding healthy tissue as much as possible.
Treatment selection depends on the tumor type, location, and stage, as well as the patient’s overall health. These factors influence whether clinicians consider surgery, radiation, systemic therapy, or local ablation, either alone or in combination. Precise tumor characterization is therefore important because it connects the biological and anatomical features of disease with a suitable treatment strategy.
Combining approaches can address the disease through different treatment strategies rather than relying on one modality alone. Local methods such as surgery or ablation may be paired with chemotherapy, targeted therapy, or immunotherapy to support tumor reduction and disease control. The choice depends on the tumor and patient context, with goals that may include preventing recurrence and extending survival.
Before treatment is selected, clinicians need precise characterization of the tumor and an assessment of its location, type, and stage. They must also consider the patient’s overall health. This information helps determine whether a local or systemic approach is appropriate, whether treatments should be combined, and how strongly the plan should prioritize tumor control or preservation of healthy tissue.
These treatments may be used to shrink tumors, relieve symptoms, prevent recurrence, or extend survival. The intended outcome depends on the disease and the selected approach, rather than on destruction alone. A plan may focus on controlling the tumor while preserving healthy tissue, or it may combine modalities when broader disease management is needed.